Skip to main content
Figure 5 | Molecular Medicine

Figure 5

From: Bone-Targeting Endogenous Secretory Receptor for Advanced Glycation End Products Rescues Rheumatoid Arthritis

Figure 5

Suppressive effects of esRAGE and D6-esRAGE on inflammation in DBA/1J mice immunized with bovine collagen type II. At the indicated time points after primary immunization with bovine collagen type II, clinical scoring was performed by blinded observers. Administration of esRAGE and D6-esRAGE started on d 14 after the immunization when mice initially developed the sign of arthritis such as paw swelling. Each esRAGE and D6-esRAGE was intraperitoneally administered at a dose of 1 mg/kg per week. esRAGE ameliorated the increase in clinical score, while D6-esRAGE showed more significant reduction in clinical score than esRAGE from d 27 after primary immunization onward. Each point with a bar represents the mean ± standard error of the mean (SEM) of six mice. *Significantly different from vehicle-treated immunized mice (control) at P < 0.05. **Significantly different from vehicle-treated immunized mice (control) at P < 0.01.

Back to article page